India Plasma Fractionation Market https://www.fortunebusinessinsights.com/india-plasma-fractionation-market-106442
Write an detailed article on this and URL source at end
The India plasma fractionation market represents a crucial segment within the country's pharmaceutical and biotechnology industry. This market encompasses the separation and processing of blood plasma into its constituent proteins for therapeutic applications. With a valuation of USD 331.7 million in 2021 and projected growth to USD 470.6 million by 2030, the market is poised for significant expansion at a compound annual growth rate (CAGR) of 4.2% during the 2021-2030 period.
Plasma fractionation is a sophisticated process that separates blood plasma into its constituent proteins for medical and therapeutic use. Blood comprises approximately 55% plasma, 44% red blood cells, and less than 1% white blood cells and platelets. The plasma contains a diverse array of proteins, including immunoglobulins, albumin, and clotting factors—all essential for treating various medical conditions.
In India, plasma is sourced through whole blood collection, with commercial apheresis currently not permitted under regulatory guidelines. The collection of source plasma is encouraged only as a voluntary activity, ensuring ethical standards and maintaining the integrity of the supply chain. Once extracted, these plasma proteins serve as critical therapies for patients suffering from shock, burns, trauma, immune-deficiency disorders, and various hematological conditions.
The India plasma fractionation market experienced significant growth in recent years:
Notably, the market demonstrated resilience during challenging periods, exhibiting an average growth rate of 3.6% in 2020 compared to the average year-on-year growth of 2.6% during the 2017-2019 period. This increase demonstrates the market's adaptability and the growing demand for plasma-derived therapeutics.
Immune-deficiency disorders represent a significant market driver, with multiple conditions requiring plasma protein therapies. According to the India Fit Report 2020, approximately 20.8% of India's population suffers from low immunity levels, significantly increasing the potential patient pool requiring treatment with plasma proteins. Common immune-deficiency disorders treated with plasma fractionation products include:
The rising incidence of patients suffering from trauma, burns, and shock has bolstered market demand. These acute medical emergencies require immediate plasma protein interventions to stabilize patients and facilitate recovery.
The market has witnessed increased adoption of clotting factors for treating hemophilia, including both Hemophilia A and Hemophilia B. This growing therapeutic application has expanded the market's revenue base and clinical relevance.
Market players have demonstrated strategic commitment to expanding production capacities to meet increasing demand. This expansion reflects confidence in market growth and availability of capital for facility development.
The COVID-19 pandemic unexpectedly accelerated market growth, creating both challenges and opportunities. The surge in demand for immunoglobulins during 2020 positively impacted market dynamics:
Increased Antibody Production: The Fourth National Serosurvey conducted by the Indian Council of Medical Research (ICMR) in July 2021 revealed that approximately 68% of India's population had developed antibodies against COVID-19, underscoring the need for immunoglobulin therapies.
Product Innovation: Companies responded to pandemic demands with innovative solutions. For example, in August 2020, Intas Pharmaceuticals Ltd. developed COVID-19 specific Hyperimmune Globulin for treating patients with moderate to severe COVID-19 infection—a critical therapeutic option before vaccine availability.
Revenue Growth: Intas Pharmaceuticals Ltd. registered a remarkable revenue of USD 2,447.7 million in 2020, representing a year-on-year growth of 12.0% from USD 2,185.4 million in 2019, largely driven by high demand for immunoglobulin products.
Market participants are actively pursuing strategic initiatives to strengthen their market positions:
Reliance Life Sciences Investment: In August 2021, Reliance Life Sciences announced a major investment of USD 282.0 million in Maharashtra Industrial Development Corporation, focusing on research and manufacturing of plasma proteins and related products. This represents significant capital infusion signaling confidence in the market's growth potential.
Companies are continuously developing innovative plasma protein therapeutics for treating various immune-deficiency disorders, positioning themselves for sustained growth in the coming years.
The Indian plasma fractionation market is characterized by:
The India plasma fractionation market stands at a pivotal juncture, with strong growth momentum and expanding therapeutic applications. With a projected CAGR of 4.2% through 2030, the market is poised to reach USD 470.6 million, driven by rising disease prevalence, technological innovation, and strategic investments from major pharmaceutical players. The pandemic's silver lining in boosting market awareness and demand underscores the critical importance of plasma-derived therapeutics in India's healthcare ecosystem.
As companies like Reliance Life Sciences and Intas Pharmaceuticals continue their strategic expansions and product innovations, the Indian plasma fractionation market is likely to emerge as a key player in both domestic healthcare delivery and potentially in the global therapeutic protein market.
Fortune Business Insights - India Plasma Fractionation Market
https://www.fortunebusinessinsights.com/india-plasma-fractionation-market-106442